AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AstraZeneca Plc's (NASDAQ: AZN) top-selling Tagrisso drug has been approved for use in the European Union to treat patients with a type of early-stage lung cancer. The European Commission has approved the lung cancer drug as an add-on (adjuvant) treatment for adults diagnosed early enough for the tumor to be surgically removed and have a mutation of the EGFR gene.

AstraZeneca's Tagrisso Wins European Approval In Early Lung Cancer

Fast-growing AstraZeneca might make an interesting addition to your portfolio.

Is It Too Late to Buy the Most Promising Pipeline in the Pharma Industry?

Johnson & Johnson

Novavax

Several of these vaccine makers face challenges.

COVID Vaccine Update: Where J&J, AstraZeneca, Novavax, and Sinovac Stand Now

AstraZeneca PLC (LON:AZN) said Tagrisso has been approved in the EU for the adjuvant treatment of adult patients with a type of early-stage lung cancer. It targets epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) which has already been tried to be removed surgically.

AstraZeneca receives EU approval for lung cancer drug Tagrisso

German scientists at Goethe University have claimed to know why some COVID-19 vaccines can cause blood clots. AstraZeneca PLC (LON:AZN) and Johnson & Johnson (NYSE:JNJ) have both developed DNA-based formulations that have been linked to very rare cases of blood clots, some of which caused death.

German scientists claim to know why AstraZeneca, Johnson & Johnson COVID-19 vaccines cause blood clots

Alexion Pharma

AstraZeneca PLC (LON:AZN) announced it has priced €800mln (£691mln) of fixed-rate notes related to the proposed acquisition of Alexion Pharmaceuticals, Inc. They have a coupon of 0.375% maturing in 2029, but must be redeemed before the maturity date if the deal doesn't happen before 12 March 2022 or if it gets scrapped.

AstraZeneca prices £691mln bond offering linked to Alexion Pharmaceuticals, Inc. acquisition

The European Union took on AstraZeneca Plc (NASDAQ: AZN) in a Brussels court and accused it of diverting doses promised to the bloc to other nations. EU's lawyer, Rafael Jafferali, asked the court to force the company to pay €10 per dose for each day of delay as compensation for breaching the EU contract, reports Reuters.

EU Seeks Fines For AstraZeneca Over COVID-19 Vaccine Delays: Reuters

The U.K. competition regulator is mulling over AstraZeneca Plc's (NASDAQ: AZN) $39 billion takeover taker of Alexion Pharmaceuticals Inc (NASDAQ: ALXN) over competition concern. The U.K.'s Competition and Markets Authority is starting the first phase of the probe today and said it should wrap it up by 21 July, deciding at that point whether to start a second, more in-depth appraisal of the deal.

UK Competition Watchdog Probes AstraZeneca's $39B Alexion Takeover

The deal, which would be financed by a $25 billion capital increase once it is concluded, was approved by AstraZeneca shareholders two weeks ago.

U.K. Watchdog to Investigate AstraZeneca's $39 Billion Alexion Takeover

The deal has already been approved by the U.S. and Canadian authorities.

AstraZeneca's $39 billion takeover of U.S.-based Alexion Pharmaceuticals examined by U.K. regulator

AstraZeneca PLC's (LON:AZN) proposed US$39bn (£27.5bn) acquisition of Alexion Pharmaceuticals, Inc. is now under investigation by the Competition and Markets Authority (CMA).

AstraZeneca £27.5bn acquisition of Alexion under investigation by competition watchdog

Silence Therapeutics PLC (LON:SLN, NASDAQ:SLN) said it has received the final US$40mln from a US$80mln cash and equity investment from AstraZeneca, adding that it expects to be working on up to five targets in the next three years with the Anglo-Swedish giant. The collaboration, which was inked last March, provides AZ scientists with access to Silence's small interfering RNA, or siRNA technology, and specifically the mRNAi GOLD platform.

Silence Therapeutics receives US$40mln tranche from AstraZeneca tie-up

Britain's competition regulator said on Tuesday it was probing if AstraZeneca's $39 billion takeover of U.S. drugmaker Alexion could reduce competition for products and services in the country or elsewhere.

Britain looking into AstraZeneca-Alexion deal for competition concerns

AstraZeneca's (AZN) COVID-19 vaccine Vaxzevria gets an approval for emergency use in Japan for active immunization of individuals aged 18 years and older.

AstraZeneca's (AZN) Coronavirus Vaccine Gets EUA in Japan

BioNTech SE

Pfizer

In this week's coronavirus (COVID-19) vaccine news, the UK has reached the 60mln milestone of administered doses.  That includes 22mln people having received both shots required to complete the immunisation course.

Coronavirus vaccines: UK hits 60mln doses milestone as new study proves AstraZeneca, Pfizer/BioNTech jabs work against Indian variant

Along with the approval of Moderna's COVID-19 vaccine, Japan's regulatory authority has also approved AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine, Vaxzevria for adults. According to Japan's public broadcaster NHK, Japan's health ministry plans not to use the AstraZeneca vaccine in public inoculation programs for the time being, even after the approval.

Japan Approves AstraZeneca's COVID Vaccine, But Puts Use on Hold Amid Blood Clot Concern

Moderna

Japan has approved the COVID-19 vaccines produced by Moderna Inc (NASDAQ:MRNA) and by AstraZeneca PLC (LON:AZN) in conjunction Oxford University, for people aged over 18. Japan has so far only vaccinated around 2% of its population of 125mln, using the Pfizer jab.

AstraZeneca and Moderna receive approval for COVID-19 vaccines in Japan

AstraZeneca PLC (LON:AZN) announced that the COVID-19 vaccine developed with Oxford University has been granted special approval for emergency use in Japan in people aged over 18. The jab, now called Vaxzevria, will be administered in two doses given four to 12 weeks apart.

AstraZeneca receives approval for COVID-19 vaccine in Japan

AstraZeneca PLC's (LON;AZN) Covid-19 vaccine gives between 85-90% effectiveness after two shots, Public Health England said today after analysing data from those inoculated so far. That puts the Astra/Oxford University candidate almost on par with the Pfizer/BioNTech vaccine, which showed 90% effectiveness compared to unvaccinated people.

AstraZeneca vaccine up to 90% effective 'real-life data' indicates

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca will present new data underscoring its ambition to redefine cancer care at the American Society of Clinical Oncology (ASCO) Annual Meeting, June 4 to 8, 2021. More than 100 abstracts will feature 21 approved and potential new medicines across the Company's industry-leading oncology portfolio, with four abstracts selected as late-breakers, 12 oral presentations and one plenary presentation. Dave Fredrickson, Executive Vice President, Oncology Busine

AstraZeneca ASCO 2021 Data Support Ambition to Revolutionize Cancer Outcomes by Treating Earlier and Transforming the Patient Experience

AstraZeneca Plc (NASDAQ: AZN) has announced results from a new integrated analysis, including data from the MELTEMI Phase 3 open-label extension trial, evaluating Fasenra (benralizumab) in adult patients with severe asthma. Results were presented today at the American Thoracic Society 2021 International Conference.

New Five-Year Data Shows Durable Efficacy Of AstraZeneca's Fasenra For Asthma Treatment

AstraZeneca PLC (NASDAQ:AZN) is in the spotlight today, after the Financial Times reported that the company's Covid-19 vaccine works well as a third booster shot, according to a study by Oxford University, the vaccine's co-developer.

AZN Adds to Vaccine Buzz on New Study

Oxford University and AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine works well as a third booster shot, according to a study, the Financial Times reported citing people familiar with the matter. A third booster shot showed "strong enough against any variant," despite concern that the immune system might fight off the adenovirus used as a delivery mechanism.

Oxford/AstraZeneca Third Booster Strong Enough Against COVID-19 Variants, Study Shows: FT

Vaccine makers, including Pfizer, Johnson & Johnson, AstraZeneca, and BioNTech, are set to make billions for many years to come.

Vaccine Makers Will Make Billions For Years To Come: Which One To Buy Now

Oxford BioMedica Plc (OTC: OXBDF) has raised its forecast for cumulative revenues from AstraZeneca Plc (NASDAQ: AZN) by the end of 2021 to more than £100 million from £50 million pounds earlier. The company did not provide any other details on its deal.

News for AstraZeneca Stock (AZN)